Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Colorcon
Merck
McKesson
Harvard Business School

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CONTRAVE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Contrave

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00563563 A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent Completed Orexigen Therapeutics, Inc Phase 2 2007-10-01 The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.
NCT01601704 Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) Terminated Orexigen Therapeutics, Inc Phase 3 2012-06-01 The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.
NCT02259179 Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers Completed Orexigen Therapeutics, Inc Phase 1 2014-09-01 This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different manufacturing sites. The pharmacokinetics of the two drug products will be evaluated separately in the fed and fasted state.
NCT02638129 Naltrexone/Bupropion Cardiovascular Outcomes Study Terminated Orexigen Therapeutics, Inc Phase 4 2016-01-01 The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse cardiovascular events (MACE) when given in combination with standard of care in overweight and obese participants with documented history of CV disease.
NCT03045341 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment Recruiting National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2/Phase 3 2017-02-27 This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Contrave

Condition Name

Condition Name for Contrave
Intervention Trials
Obesity 8
Binge-Eating Disorder 4
Overweight 2
Nicotine Dependence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Contrave
Intervention Trials
Feeding and Eating Disorders 4
Bulimia 4
Binge-Eating Disorder 4
Obesity 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Contrave

Trials by Country

Trials by Country for Contrave
Location Trials
United States 87
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Contrave
Location Trials
Connecticut 6
California 3
Ohio 3
Kansas 3
Arkansas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Contrave

Clinical Trial Phase

Clinical Trial Phase for Contrave
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2/Phase 3 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Contrave
Clinical Trial Phase Trials
Recruiting 4
Terminated 2
Completed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Contrave

Sponsor Name

Sponsor Name for Contrave
Sponsor Trials
Yale University 4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 4
Orexigen Therapeutics, Inc 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Contrave
Sponsor Trials
Other 6
NIH 4
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Merck
McKesson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.